Jump to content

Latanoprost

From Wikipedia, the free encyclopedia
(Redirected from Xalatan)

Latanoprost
Clinical data
Trade namesXalatan, Xelpros, Monoprost, others
AHFS/Drugs.comMonograph
MedlinePlusa697003
License data
Pregnancy
category
  • AU: B3
Routes of
administration		Topical eye drop
ATC code
Legal status
Legal status
Pharmacokinetic data
MetabolismActivation by ester hydrolysis, deactivation by beta oxidation
Onset of action3–4 hours
Elimination half-life17 minutes (plasma)
Duration of action≥ 24 hours
ExcretionMainly via kidney
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.162.178 Edit this at Wikidata
Chemical and physical data
FormulaC26H40O5
Molar mass432.601 g·mol−1
3D model (JSmol)
  (verify)

Latanoprost, sold under the brand name Xalatan among others, is a medication used to treat increased pressure inside the eye (intraocular pressure).[5] This includes ocular hypertension and open-angle glaucoma.[5] Latanaprost is applied as eye drops to the eyes.[5] Onset of effects is usually within four hours, and they last for up to a day.[5]

Common side effects include blurry vision, redness of the eye, itchiness, and darkening of the iris.[5] Latanoprost is in the prostaglandin analogue family of medications.[5] It works by increasing the outflow of aqueous fluid from the eyes through the uveoscleral tract.[6]

Latanoprost was approved for medical use in the United States and the European Union in 1996.[5][3] It is on the World Health Organization's List of Essential Medicines.[7] Latanoprost is available as a generic medication.[8] In 2021, it was the 68th most commonly prescribed medication in the United States with more than 9 million prescriptions.[9][10] It is available as a combination with netarsudil and with timolol.

Medical uses[edit]

In the United States, latanoprost is indicated for the reduction of elevated intraocular pressure in people with open-angle glaucoma or ocular hypertension.[2]

Open-angle glaucoma[edit]

Latanoprost eye drops, marketed by Pfizer
Latanoprost in Japanese-language packaging

In people with ocular hypertension (IOP ≥21 mm Hg) including open-angle glaucoma, treatment with latanoprost reduced IOP levels by 22 to 39% over 1 to 12 months’ treatment. Latanoprost is more effective than timolol 0.5% twice daily in 3 of 4 large (n = 163 to 267) randomised, double-blind trials. Latanoprost demonstrated a stable long-term IOP-lowering effect in 1- or 2-year continuations of these trials, with no sign of diminishing effect during prolonged treatment.[11]

Meta-analysis suggests that latanoprost is more effective than timolol in lowering intraocular pressure (IOP). However, it often causes iris pigmentation. While current[when?] evidence suggests that this pigmentation is benign, careful lifetime evaluation of patients is still justified.[12]

Closed-angle glaucoma[edit]

Patients who had elevated IOP despite iridotomy and/or iridectomy (including patients of Asian descent), latanoprost was significantly more effective than timolol in two double-blind, monotherapy trials (8.2 and 8.8 mm Hg vs 5.2 and 5.7 mm Hg for latanoprost vs timolol at 12 and 2 weeks, respectively).[13]

Adverse effects[edit]

Listed from most to least common:[14][15]

Research suggests that wiping the eye with an absorbent pad after the administration of eye drops can result in shorter eyelashes and a lesser chance of hyperpigmentation in the eyelid, compared to not wiping off excess fluid.[17]

Pregnancy[edit]

Interactions[edit]

Interactions are similar to other prostaglandin analogs. Paradoxically, the concomitant use of latanoprost and bimatoprost or other prostaglandins may result in increased intraocular pressure.[2] Non-steroidal anti-inflammatory drugs (NSAIDs) can reduce or increase the effect of latanoprost.[14][15]

Pharmacology[edit]

Mechanism of action[edit]

Like other prostaglandin analogues, latanoprost acid is an analog of prostaglandin F2α that acts as a selective agonist at the prostaglandin F receptor. Prostaglandins increase the sclera's permeability to aqueous fluid. By giving latanoprorost, it increases prostaglandin's scleral activity, increasing outflow of aqueous fluid and lowering intraocular pressure.[14][15] The outflow of aqueous fluid would reduce the intraocular pressure in the eye, reducing the likelihood of complications such as optic nerve damage and visual field loss.[2]

Pharmacokinetics[edit]

Latanoprost is absorbed well through the cornea. As an ester prodrug, it completely hydrolyses to the active latanoprost acid upon absorption to become biologically active.[2] Highest concentrations of the acid in the aqueous humour are reached two hours after application, lowering of intraocular pressure starts after 3 to 4 hours, with its highest effect found after 8 to 12 hours, and its effect still present for at least 24 hours. When latanoprost acid reaches the circulation, it is quickly metabolised in the liver by fatty acid beta oxidation to 1,2-dinor- and 1,2,3,4-tetranor-latanoprost acid; blood plasma half life is only 17 minutes. The metabolites are mainly excreted via the kidney, with 88% of the topical dose and 98% of an intravenous dose being recovered in the urine respectively.[14][15]

The activation and deactivation pathway is analogous to the one of tafluprost (at least up to the tetranor-metabolite);[15] compare Tafluprost#Pharmacokinetics.

Metabolism. From left to right: latanoprost, latanoprost acid (the active metabolite), 1,2-dinorlatanoprost acid, 1,2,3,4-tetranorlatanoprost acid[15]

Chemistry[edit]

Stability[edit]

Latanoprost exhibits thermal and solar instability. The concentration of latanoprost stored at 50 °C will decrease by 10% every 8.25 days. When stored at 70 °C the concentration will decrease by 10% every 1.32 days. Ultraviolet light, for example in sunlight, causes rapid degradation of latanoprost.[18]

Society and culture[edit]

Legal status[edit]

Latanoprost was approved for medical use in the United States and the European Union in 1996.[5][3]

In September 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Catiolanze, intended for the reduction of elevated intraocular pressure in adults with open angle glaucoma or ocular hypertension and in children from four years and adolescents with elevated intraocular pressure and pediatric glaucoma.[3] The applicant for this medicinal product is Santen Oy.[3] Catiolanze was approved for medical use in the European Union in November 2023.[3][4]

Brand names[edit]

Latanoprost is sold under many brand names including Xalatan,[2][19] Iyuzeh,[20] Xelpros,[21] and Catiolanze.[3]

In the US, Xalatan is marketed by Viatris after Upjohn was spun off from Pfizer.[22][23][24]

Cosmetic use[edit]

  • Lengthening and thickening of the eyelashes (used, like bimatoprost, in the cosmetic industry as eyelash growth enhancers).[25]

References[edit]

  1. ^ "Latanoprost 50 micrograms/ml eye drops, solution - Summary of Product Characteristics (SmPC)". (emc). 1 July 2022. Archived from the original on 1 July 2022. Retrieved 1 July 2022.
  2. ^ Jump up to: a b c d e f "Xalatan- latanoprost solution". DailyMed. 27 December 2022. Archived from the original on 30 March 2023. Retrieved 30 March 2023.
  3. ^ Jump up to: a b c d e f g "Catiolanze EPAR". European Medicines Agency (EMA). 14 September 2023. Archived from the original on 5 December 2023. Retrieved 11 December 2023.
  4. ^ Jump up to: a b "Catiolanze Product information". Union Register of medicinal products. 16 November 2023. Retrieved 11 December 2023.
  5. ^ Jump up to: a b c d e f g h "Latanoprost Monograph". The American Society of Health-System Pharmacists. Archived from the original on 28 December 2016. Retrieved 8 December 2016.
  6. ^ Patel SS, Spencer CM (1996). "Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension". Drugs Aging. 9 (5): 363–378. doi:10.2165/00002512-199609050-00007. PMID 8922563. S2CID 25169085.
  7. ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
  8. ^ Hamilton R (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 413. ISBN 9781284057560.
  9. ^ "The Top 300 of 2021". ClinCalc. Retrieved 14 January 2024.
  10. ^ "Latanoprost - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
  11. ^ Perry CM, McGavin JK, Culy CR, Ibbotson T (2003). "Latanoprost. An Update of its Use in Glaucoma and Ocular Hypertension". Drugs & Aging. 20 (8): 597–630. doi:10.2165/00002512-200320080-00005. PMID 12795627. S2CID 24493058.
  12. ^ Zhang WY, Wan Po AL, Dua HS, Azuara-Blanco A (2001). "Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension". British Journal of Ophthalmology. 85 (8): 983–990. doi:10.1136/bjo.85.8.983. PMC 1724079. PMID 11466259.
  13. ^ Aung T, Wong HT, Yip CC, Leong JY, Chan YH, Chew PT (June 2000). "Comparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma: a preliminary study". Ophthalmology. 107 (6): 1178–1183. doi:10.1016/s0161-6420(00)00073-7. PMID 10857840.
  14. ^ Jump up to: a b c d Latanoprost Professional Drug Facts.
  15. ^ Jump up to: a b c d e f Haberfeld H, ed. (2015). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag.
  16. ^ Amano S, Nakai Y, Ko A, Inoue K, Wakakura M (2008). "A case of keratoconus progression associated with the use of topical latanoprost". Japanese Journal of Ophthalmology. 52 (4): 334–6. doi:10.1007/s10384-008-0554-6. PMID 18773275. S2CID 189795938.
  17. ^ Xu L, Wang X, Wu M (2017). "Topical medication instillation techniques for glaucoma". Cochrane Database Syst Rev. 2017 (2): CD010520. doi:10.1002/14651858.CD010520.pub2. PMC 5419432. PMID 28218404.
  18. ^ Morgan PV, Proniuk S, Blanchard J, Noecker RJ (2001). "Effect of temperature and light on the stability of latanoprost and its clinical relevance". Journal of Glaucoma. 10 (5): 401–405. doi:10.1097/00061198-200110000-00007. PMID 11711838. S2CID 26568064.
  19. ^ https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020597Orig1s000rev.pdf
  20. ^ "Drug Approval Package: Iyuzeh". accessdata.fda.gov. 20 September 2023. Retrieved 27 December 2023.
  21. ^ "Drug Approval Package: Xelpros". accessdata.fda.gov. 28 May 2019. Retrieved 27 December 2023.
  22. ^ "Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan". Pfizer. 16 November 2020. Retrieved 17 June 2024 – via Business Wire.
  23. ^ "Xalatan". Pfizer. Retrieved 17 June 2024.
  24. ^ "Brands". Viatris. 16 November 2020. Retrieved 17 June 2024.
  25. ^ Johnstone MA, Albert DM (August 2002). "Prostaglandin-induced hair growth". Survey of Ophthalmology. 47 (Suppl 1): S185–S202. doi:10.1016/S0039-6257(02)00307-7. PMID 12204716.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Latanoprost&oldid=1229507374"